Evidence map›Paper›PMID 36945568›Full record

ArticlebioRxiv : the preprint server for biology2023

A molecular glue approach to control the half-life of CRISPR-based technologies.

Vedagopuram Sreekanth, Max Jan, Kevin T Zhao, Donghyun Lim, Jessie R Davis, Marie McConkey, Veronica Kovalcik, Sam Barkal, Benjamin K Law, James Fife and 9 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Vedagopuram SreekanthChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Max JanBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Kevin T ZhaoMerkin Institute of Transformative Technologies in Healthcare, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Donghyun LimChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Jessie R DavisMerkin Institute of Transformative Technologies in Healthcare, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Marie McConkeyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Veronica KovalcikDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Sam BarkalDepartment of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Benjamin K LawChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
James FifeDepartment of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Ruilin TianInstitute for Neurodegenerative Diseases, Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA.
Michael E VinyardDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.
Basheer BecerraMolecular Pathology Unit, Massachusetts General Hospital, Charlestown, MA, USA.
Martin KampmannInstitute for Neurodegenerative Diseases, Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA.
Richard I SherwoodDepartment of Medicine, Harvard Medical School, Boston, MA 02115, USA.
Luca PinelloMolecular Pathology Unit, Massachusetts General Hospital, Charlestown, MA, USA.
David R LiuMerkin Institute of Transformative Technologies in Healthcare, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Benjamin L EbertBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Amit ChoudharyChemical Biology and Therapeutics Science Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Funding

Center for Genomic Editing and Recording: Development and Application of Next-Generation Genome and Epigenome Editing Methods to Advance the Study and Treatment of Human DiseaseRM1HG009490 · NHGRI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI Brittany S. Adamson, Martin Joseph Ankrah Aryee · 2017 to 2026
$22.7M
Training Program in Bioinformatics and Integrative GenomicsT32HG002295 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Peter J Park · 2001 to 2026
$15.8M
Integrating Chemistry and Evolution to Illuminate Biology and Enable Novel TherapeuticsR35GM118062 · NIGMS · HARVARD UNIVERSITY · PI LIU, DAVID R · 2016 to 2025
$6.4M
The role of clonal hematopoiesis in the development and therapy of myeloid malignanciesR35CA253125 · NCI · DANA-FARBER CANCER INST · PI EBERT, BENJAMIN LEVINE · 2020 to 2024
$4.9M
Development of platforms for sorting, production, editing of beta cellsR01DK132900 · NIDDK · BROAD INSTITUTE, INC. · PI Amit Choudhary, Neal Krishna Devaraj · 2023 to 2026
$2.6M
Multiscale exploration of the functional non-coding genomeR35HG010717 · NHGRI · MASSACHUSETTS GENERAL HOSPITAL · PI PINELLO, LUCA · 2019 to 2023
$2.6M
Delivery Technologies for In Vivo Genome EditingUG3AI150551 · NIAID · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CHAIKOF, ELLIOT · 2019 to 2021
$2.3M
Expanding the Scope of Base EditingU01AI142756 · NIAID · BROAD INSTITUTE, INC. · PI LIU, DAVID R · 2018 to 2022
$2.1M
Chemical approaches for precision genome editingR01GM137606 · NIGMS · BROAD INSTITUTE, INC. · PI CHOUDHARY, AMIT · 2021 to 2024
$1.5M
Development of synthetic gene drives using small moleculesR01GM132825 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI AKBARI, OMAR SULTAN, CHOUDHARY, AMIT · 2019 to 2022
$1.4M
NCI NIH HHS R35 CA253125NHGRI NIH HHS R35 HG010717NHGRI NIH HHS RM1 HG009490NHGRI NIH HHS T32 HG002295NIAID NIH HHS U01 AI142756NIAID NIH HHS UG3 AI150551NIDDK NIH HHS R01 DK132900NIGMS NIH HHS R01 GM132825NIGMS NIH HHS R01 GM137606NIGMS NIH HHS R35 GM118062
6 · The paper itself

Abstract

Cas9 is a programmable nuclease that has furnished transformative technologies, including base editors and transcription modulators (e.g., CRISPRi/a), but several applications of these technologies, including therapeutics, mandatorily require precision control of their half-life. For example, such control can help avert any potential immunological and adverse events in clinical trials. Current genome editing technologies to control the half-life of Cas9 are slow, have lower activity, involve fusion of large response elements (> 230 amino acids), utilize expensive controllers with poor pharmacological attributes, and cannot be implemented

Identifiers

PMID36945568
PMCPMC10028966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.